title: Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.
authors.affiliation: Departments of Biochemical & Cellular Pharmacology, Genentech, Inc., South San Francisco, CA 94080, USA.
authors.forename: Yanmei
authors.identifier: 0000-0002-2772-5154
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
authors.forename: Leslie A
authors.identifier: 0000-0002-7346-2818
authors.initials: LA
authors.lastname: Khawli
authors.affiliation: UCB Pharma, Slough, Berkshire SL1 14EN, UK.
authors.forename: Shobha
authors.identifier: 0000-0002-0015-1357
authors.initials: S
authors.lastname: Purushothama
authors.affiliation: UCB Pharma, Slough, Berkshire SL1 14EN, UK.
authors.forename: Frank-Peter
authors.initials: FP
authors.lastname: Theil
authors.affiliation: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.
authors.forename: Michael A
authors.identifier: 0000-0001-6699-8473
authors.initials: MA
authors.lastname: Partridge
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D001688:Biological Products / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D001691:Biological Therapy / Q000009:adverse effects / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007518:Isoantibodies / Q000097:blood / Q000276:immunology; D011506:Proteins / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products; D007518:Isoantibodies; D011506:Proteins